Keywords
How to Cite
Abstract
Glioblastomas are characterized by a variety of genetic and epigenetic disorders, identification of which allows constantly expanding a list of genes directly involved in carcinogenesis, thus increasing molecular diagnostics, monitoring and predicting disease. Molecular-genetic studies of patients with glioblastomas allowed revealing changes relevant to this disease and determining their prognostic significance. In the future molecular-biological markers along with clinical and therapeutic factors may play a role of separate and independent factors of prognosis in patients with malignant brain lesions.References
Борисов К. Е., Сакаева Д. Д. Генные нарушения и молекулярно-генетические подтипы злокачественных глиом // Архив патол. - 2013. № 3. -С. 52-61.
Бывальцев В. А., Степанов И. А.,Белых Е. Г и др. Молекулярная биология глиом высокой степени злокачественности // Сиб. мед. журнал (Иркутск). - 2015. № 2. - С. 5-9.
Измайлов Т. Р., Паньшин Г. А., Даценко П. В. Выбор режима фракционирования при л ечеНИИ глиом высокой степени злокачественности (часть 1): возраст и степень злокачественности // Сиб. онкол. журнал. 2012. № 2. (50). С. 11-17.
Измайлов Т. Р., Паньшин Г. А., Даценко П. В. Выбор режима фракционирования при лечении глиом высокой степени злокачественности (часть 2): функциональное состояние и классы RPA // Сиб. онкол. журнал. 2012. № 3. (51). С. 54-59.
Омаров А. Д., Копачев Д. Н., Саникидзе А. З. и др. Лечение гидроцефалии опухолевой этиологии. Современное состояние проблемы // Вестн. Росс. научн. центра рентгенорадиологии.
Caggana M., Kilgallen J., Conroy J. M. et al. Associations between ERCC2 polymorphisms and gliomas // Cancer Epidemiol Biomarkers Prev. - 2010. - Vol. 10. P. 355 -360.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 // URL http://www. cbtrus. org/2012-NPCR-SEER/CBTRUS_Report_2004-2008_3-23-2012. pdf.
Ferlay J., Shin H. R., Bray F., et al. GLOBOCAN 2008. Vol. 1. 2. Cancer Incidence and Mortality Worldwide IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010. URL: http://globocan. ia
Fritz A., Percy C., Jack A. et al. International Classification of Diseases for Oncology, Third edition. World Health Organization, 2000.
Hegi M. E., Diserens A. C., Gorlia T. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma // N Engl J Med. - 2005. -Vol. 352. - P 997-1003.
Li J, Wang M, Won M et al. Validation and Simplification of the Radiation Therapy oncology group recursive partitioning analysis classification for glioblastoma // Int J Radiat Oncol Biol Phys. 2010 Sep 30. [Epub ahead of print]. URL:_http://www. ncbi. nlm.
Louis D. N., Holland E. C., Cairncross J. G., et al. Glioma classification: a molecular reappraisal // Am J Pathol. -2001. - Vol. 159. - P 779-786.
Louis D. N. Molecular pathology of malignant glioma // Ann Rev Pathol Mech Dis. - 2006. - Vol. 1. - P. 97-117.
Matsuda M, Yamamoto T, Ishikawa E. et al. Prognostic factors in glioblastoma multiforme patients receiving highdose particle radiotherapy or conventional radiotherapy. Br J Radiol. 2011. - Vol. 84 (1). - P. S54-56.
Mizusawa, H., Ishii T., Bannai S. - 2000. Neurosci. Lett. 283- P. 57-60.
Noushmehr H., Weisenberger D. J., Diefes K. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma // Cancer Cell. - 2010. - Vol. 17. - P. 510-522.
Nutt C., Nutt C. L., Mani D. R. et al: Gene expression-based classification of ma lignant gliomas correlates better with survival than histological classification // Cancer Res. - 2003. - Vol. 63. - P. 1602-1607.
Parkin D. M., Whelan S. L., Ferlay J., Storm H. Cancer Incidence in Five Continents. Vol. I to VIII. IARC Cancer Base No. 7. - Lyon. - 2005.
Parsons D. W., Jones S., Zhang X. et al. An integrated genomic analysis of human glioblastoma multiforme // Science. 2008. - Vol. 321. - P. 1807-1812.
Pignatti F., van den Bent M., Curran D. et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma // J Clin Oncol. 2002. - Vol. 20 (8). - P. 2076-2084.
Rivera A. L., Pelloski C. E., Gilbert M. R. et al: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma // Neuro Oncol. - 2010. - Vol. 12. - P 116-121.
Sanson M., Marie Y, Paris S. et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas // J Clin Oncol. - 2009. - Vol. 27. - P. 4150-4154.
Smith J. S., Tachibana I., Passe S. M. et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme // J Natl Cancer Inst. - 2001. - Vol. 93. - P 1246-1256.
Sulman E. P, Guerrero M., Aldape K. et al. Beyond grade: molecular pathology of malignant gliomas // Semin Ra-diat Oncol. - 2009. - Vol. 19. - P 142-149.
TCGA Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways // Nature. - 2008. - Vol. 455. - P. 1061-1068.
Verhaak R. G., Hoadley K. A., Purdom E. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 // Cancer Cell. - 2010. - Vol. 6. - P 98-110.
Vescovi A. L., Galli R., Reynolds B. A. et al: Brain tumour stem cells // Natl Rev Cancer. - 2006. - Vol. 6. - P 425436 CrossRef.
Yip S., Miao J., Cahill D. P et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance // Clin Cancer Res. - 2009. -Vol. 15. - P 4622-4629.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...